MDxHealth Cuts Q4 Revenue by $1M, Sees 28% 2026 Growth with 10% EBITDA Target
A $1 million downward adjustment to Q4 revenue forecasts due to integration complexities from the exoDX acquisition contributed to lower-than-expected EBITDA and higher cash burn. Management projects roughly 28% revenue growth for 2026, targeting a 10% EBITDA margin by year-end through fixed operating expenses and stable low-60% gross margins.
1. Q4 Revenue Adjustment and Integration Complexities
MDxHealth reported a $1 million downward adjustment to its pre-release Q4 revenue estimate, reflecting complexities in closing processes following the exoDX acquisition and integration of new systems. This adjustment represents the impact of delayed customer transitions and billing reconciliations on reported figures.
2. Q4 EBITDA Decline and Cash Flow Impact
The adjusted revenue contributed to lower-than-expected EBITDA and increased cash burn in the fourth quarter. Management noted that operating expenses as a percentage of revenue are declining, but the timing of acquisition-related costs temporarily pressured margins.
3. 2026 Revenue Guidance
For fiscal 2026, management targets a midpoint implying roughly 28% year-over-year revenue growth, driven by balanced expansion across tissue and liquid diagnostic products and contributions from the exoDX acquisition. The company plans to leverage its expanded customer base to help achieve or exceed this guidance.
4. Margin Targets and Operating Leverage
MDxHealth aims for a 10% EBITDA margin by year-end, maintaining fixed selling, general and administrative expenses while growing revenue. Gross margins are expected to remain in the low 60% range, with improvements sought through pricing strategies and operational efficiencies.